Zenith Health Care submitted its 32nd Annual Report to the Bombay Stock Exchange (BSE) on August 4, 2026. The filing was made in compliance with Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory submission ensures that shareholders and stakeholders have access to the company's audited financial statements and management discussion for the relevant fiscal year.

The document was authorized by Akshit M. Raycha, Joint Managing Director of Zenith Health Care. Raycha digitally signed the submission letter addressed to BSE Ltd., located at Floor 25, P J Towers, Dalal Street, Mumbai. The reference number for this filing is ZHL/LODR-AGM/2026/0581.

Filing Details

Regulation 34 mandates that listed entities submit their annual reports to stock exchanges within a specified timeframe after the conclusion of the Annual General Meeting. This requirement facilitates transparent disclosure of corporate governance practices, financial performance, and operational updates to the investing public.

Zenith Health Care is identified by Security Code 530665 and Security ID ZENITHHE on the exchange. The company's ISIN is INE812B01026. Investors are advised to refer to the full annual report for detailed financial metrics and strategic insights not included in this brief regulatory notice.

Zenith Health Care will hold its 32nd Annual General Meeting (AGM) on August 28, 2026, seeking shareholder approval for a material related-party transaction (RPT) valued up to ₹100 crore with Achyut Healthcare Limited. The meeting, conducted via video conferencing, also covers the adoption of FY26 financial results, which reported a Profit After Tax (PAT) of ₹0.51 lakh, down from ₹6.70 lakh in FY25. Shareholders must act before the book closure ends on August 28, 2026, to vote on these critical governance and financial matters.

The RPT involves the sale of Active Pharmaceutical Ingredients (APIs), raw materials, and packing materials to Achyut Healthcare Limited, identified as a related party under Section 2(76) of the Companies Act, 2013. The transaction requires approval under Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it exceeds materiality thresholds. The Board of Directors states that these transactions are conducted at arm’s length in the ordinary course of business, noting that certain licenses and approvals are registered under Achyut Healthcare Limited.

Key Dates and Voting Schedule

Remote e-voting through National Securities Depository Limited (NSDL) will run from August 25, 2026, to August 27, 2026. The Register of Members and Share Transfer Books will remain closed from August 22, 2026, to August 28, 2026. Only shareholders recorded as of the cut-off date — August 21, 2026 — are eligible to vote.

Director Re-appointments

The AGM will also consider the re-appointment of key executives. Mahendra C Raycha seeks re-appointment as Managing Director for three years, effective July 1, 2026, due to attaining the age of 70 years. His remuneration includes a basic salary of ₹2,00,000 per month plus perquisites. Akshit M Raycha is up for regularization as Joint Managing Director/Whole Time Director for three years, effective May 29, 2026, with total remuneration capped at ₹24,00,000 per annum. Additionally, Mrs. Neela M Raycha retires by rotation and offers herself for re-appointment as Director.

Financial Performance

The company’s financials for FY26 show a significant contraction in profitability. Total income stood at ₹1,093.65 lakh, compared to ₹1,176.11 lakh in FY25. Expenditure and depreciation were ₹1,092.05 lakh, resulting in a Profit Before Tax (PBT) of ₹1.60 lakh, a sharp decline from ₹27.92 lakh in the previous year. After tax provisions of ₹1.09 lakh, PAT dropped to ₹0.51 lakh.

What the Numbers Show

The convergence of the book closure announcement with the AGM agenda highlights the immediate importance of the upcoming vote for investors. With the company reporting a sharp contraction in net profitability — PAT fell by approximately 92% year-on-year — the approval of the ₹100 crore related-party deal becomes a critical governance checkpoint. Investors must assess whether the arm’s length nature of the transaction with Achyut Healthcare Limited offers strategic value sufficient to offset the recent operational profit squeeze. The zero-debt status provides a buffer, but the reliance on related-party channels for API sales warrants close scrutiny during the voting period.